^
Association details:
| Biomarker: | EGFR mutation + PTEN deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) + REGN5093-M114 (Tubulin inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Published date:
01/04/2023
Excerpt:
REGN5093-M114 potently reduced tumor growth of EGFR-mutant NSCLC with PTEN loss or MET Y1230C mutation after progression on prior osimertinib and savolitinib treatment...Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.
DOI:
10.1158/1078-0432.CCR-22-2180
